ADMA
Price
$17.75
Change
-$0.53 (-2.90%)
Updated
Jan 15, 11:08 AM (EDT)
Capitalization
4.35B
63 days until earnings call
Intraday BUY SELL Signals
AUPH
Price
$15.08
Change
-$0.15 (-0.98%)
Updated
Jan 15, 11:11 AM (EDT)
Capitalization
2.01B
48 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ADMA vs AUPH

Header iconADMA vs AUPH Comparison
Open Charts ADMA vs AUPHBanner chart's image
ADMA Biologics
Price$17.75
Change-$0.53 (-2.90%)
Volume$500
Capitalization4.35B
Aurinia Pharmaceuticals
Price$15.08
Change-$0.15 (-0.98%)
Volume$200
Capitalization2.01B
ADMA vs AUPH Comparison Chart in %
View a ticker or compare two or three
VS
ADMA vs. AUPH commentary
Jan 15, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ADMA is a Hold and AUPH is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jan 15, 2026
Stock price -- (ADMA: $18.28 vs. AUPH: $15.23)
Brand notoriety: ADMA and AUPH are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ADMA: 63% vs. AUPH: 63%
Market capitalization -- ADMA: $4.35B vs. AUPH: $2.01B
ADMA [@Biotechnology] is valued at $4.35B. AUPH’s [@Biotechnology] market capitalization is $2.01B. The market cap for tickers in the [@Biotechnology] industry ranges from $114.05B to $0. The average market capitalization across the [@Biotechnology] industry is $2.27B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ADMA’s FA Score shows that 2 FA rating(s) are green whileAUPH’s FA Score has 0 green FA rating(s).

  • ADMA’s FA Score: 2 green, 3 red.
  • AUPH’s FA Score: 0 green, 5 red.
According to our system of comparison, ADMA is a better buy in the long-term than AUPH.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ADMA’s TA Score shows that 4 TA indicator(s) are bullish while AUPH’s TA Score has 4 bullish TA indicator(s).

  • ADMA’s TA Score: 4 bullish, 5 bearish.
  • AUPH’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, AUPH is a better buy in the short-term than ADMA.

Price Growth

ADMA (@Biotechnology) experienced а -2.87% price change this week, while AUPH (@Biotechnology) price change was -4.93% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.31%. For the same industry, the average monthly price growth was +3.20%, and the average quarterly price growth was +43.69%.

Reported Earning Dates

ADMA is expected to report earnings on Mar 19, 2026.

AUPH is expected to report earnings on Mar 04, 2026.

Industries' Descriptions

@Biotechnology (+0.31% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ADMA($4.35B) has a higher market cap than AUPH($2.01B). AUPH has higher P/E ratio than ADMA: AUPH (27.20) vs ADMA (21.26). ADMA YTD gains are higher at: 0.219 vs. AUPH (-4.514). ADMA has higher annual earnings (EBITDA): 172M vs. AUPH (104M). AUPH has more cash in the bank: 352M vs. ADMA (61.4M). AUPH has less debt than ADMA: AUPH (78.2M) vs ADMA (83.1M). ADMA has higher revenues than AUPH: ADMA (489M) vs AUPH (266M).
ADMAAUPHADMA / AUPH
Capitalization4.35B2.01B217%
EBITDA172M104M165%
Gain YTD0.219-4.514-5%
P/E Ratio21.2627.2078%
Revenue489M266M184%
Total Cash61.4M352M17%
Total Debt83.1M78.2M106%
FUNDAMENTALS RATINGS
ADMA vs AUPH: Fundamental Ratings
ADMA
AUPH
OUTLOOK RATING
1..100
5360
VALUATION
overvalued / fair valued / undervalued
1..100
74
Overvalued
76
Overvalued
PROFIT vs RISK RATING
1..100
3299
SMR RATING
1..100
1744
PRICE GROWTH RATING
1..100
5639
P/E GROWTH RATING
1..100
98100
SEASONALITY SCORE
1..100
n/a75

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ADMA's Valuation (74) in the Biotechnology industry is in the same range as AUPH (76). This means that ADMA’s stock grew similarly to AUPH’s over the last 12 months.

ADMA's Profit vs Risk Rating (32) in the Biotechnology industry is significantly better than the same rating for AUPH (99). This means that ADMA’s stock grew significantly faster than AUPH’s over the last 12 months.

ADMA's SMR Rating (17) in the Biotechnology industry is in the same range as AUPH (44). This means that ADMA’s stock grew similarly to AUPH’s over the last 12 months.

AUPH's Price Growth Rating (39) in the Biotechnology industry is in the same range as ADMA (56). This means that AUPH’s stock grew similarly to ADMA’s over the last 12 months.

ADMA's P/E Growth Rating (98) in the Biotechnology industry is in the same range as AUPH (100). This means that ADMA’s stock grew similarly to AUPH’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ADMAAUPH
RSI
ODDS (%)
Bearish Trend 1 day ago
69%
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
88%
Bullish Trend 1 day ago
87%
Momentum
ODDS (%)
Bearish Trend 1 day ago
79%
Bearish Trend 1 day ago
84%
MACD
ODDS (%)
Bearish Trend 1 day ago
80%
N/A
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
80%
Bearish Trend 1 day ago
78%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
79%
Bearish Trend 1 day ago
82%
Advances
ODDS (%)
Bullish Trend 9 days ago
86%
Bullish Trend 9 days ago
82%
Declines
ODDS (%)
Bearish Trend 3 days ago
76%
Bearish Trend 7 days ago
81%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
83%
Aroon
ODDS (%)
Bearish Trend 1 day ago
79%
Bullish Trend 1 day ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
ADMA
Daily Signal:
Gain/Loss:
AUPH
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
OSCIX36.030.16
+0.45%
Invesco International Small-Mid Com R6
PFSVX15.040.05
+0.33%
iMGP Small Company Fund Instl Cl
JGEMX13.130.02
+0.15%
JHancock Global Equity R6
MIQBX7.04-0.01
-0.14%
Morgan Stanley Inst International Eq A
STFAX515.83-2.75
-0.53%
State Street Equity 500 Index Adm

ADMA and

Correlation & Price change

A.I.dvisor indicates that over the last year, ADMA has been loosely correlated with VIR. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if ADMA jumps, then VIR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ADMA
1D Price
Change %
ADMA100%
+3.28%
VIR - ADMA
50%
Loosely correlated
+8.08%
CPRX - ADMA
42%
Loosely correlated
+3.67%
IMTX - ADMA
40%
Loosely correlated
+4.80%
RGNX - ADMA
40%
Loosely correlated
-0.66%
AUPH - ADMA
39%
Loosely correlated
+1.60%
More

AUPH and

Correlation & Price change

A.I.dvisor indicates that over the last year, AUPH has been loosely correlated with JSPR. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if AUPH jumps, then JSPR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AUPH
1D Price
Change %
AUPH100%
+1.60%
JSPR - AUPH
44%
Loosely correlated
+3.85%
MLTX - AUPH
40%
Loosely correlated
+1.81%
KALA - AUPH
40%
Loosely correlated
+3.87%
ADMA - AUPH
39%
Loosely correlated
+3.28%
VCYT - AUPH
39%
Loosely correlated
-1.39%
More